ASCO 2020: Update on Genitourinary Cancers

home / publications / supplements / asco-2020-gu
Dr. Pal on the Background of the COSMIC-021 Trial in ​Urothelial Cancer

Dr. Pal on the Background of the COSMIC-021 Trial in ​Urothelial Cancer

Sumanta Kumar Pal, MD
June 24th 2020
Video

Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.

Dr Agarwal on the Rationale for ​Novel Combination​ ​Therapies in ​mCRPC

Dr Agarwal on the Rationale for ​Novel Combination​ ​Therapies in ​mCRPC

Neeraj Agarwal, MD
June 24th 2020
Video

Neeraj Agarwal, MD, discusses the rationale for novel combination therapies in metastatic castration-resistant prostate cancer​.

Pal Previews Promise of Cabozantinib Plus Atezolizumab in Heavily Pretreated Urothelial Cancer

Pal Previews Promise of Cabozantinib Plus Atezolizumab in Heavily Pretreated Urothelial Cancer

Brittany Cote
June 9th 2020
Article

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

COSMIC-021 Data Affirm Activity of Cabozantinib/Atezolizumab in mCRPC

COSMIC-021 Data Affirm Activity of Cabozantinib/Atezolizumab in mCRPC

Jessica Hergert
June 8th 2020
Article

Neeraj Agarwal, MD, discusses the COSMIC-021 trial, the findings from cohort 6 in metastatic castration-resistant prostate cancer, and the planned phase 3 trial that will evaluate the combination on a larger scale.